{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:44:28Z","timestamp":1791967468317,"version":"4.3.4"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472998"],"award-info":[{"award-number":["82472998"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118530","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:09:58Z","timestamp":1791500998000},"page":"118530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P3","title":["Recent advances in tumor microenvironment-responsive pro-antibody to overcome on-target, off-tumor toxicity"],"prefix":"10.1016","volume":"254","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2646-7050","authenticated-orcid":false,"given":"Zhihao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9907-7259","authenticated-orcid":false,"given":"Ali Sahraianali","family":"Jahromi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangdong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118530_b0005","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41577-025-01207-9","article-title":"Fifty years of monoclonals: the past, present and future of antibody therapeutics","volume":"25","author":"Chan","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2026.118530_b0010","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-Label phase III Trial of Panitumumab Plus best supportive Care Compared with best supportive Care Alone in patients with Chemotherapy-Refractory Metastatic Colorectal Cancer","volume":"25","author":"Cutsem","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118530_b0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118530_b0020","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.intimp.2018.08.014","article-title":"Immune-related adverse events from combination immunotherapy in cancer patients: a comprehensive meta-analysis of randomized controlled trials","volume":"63","author":"Zhang","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2026.118530_b0025","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/jamaoncol.2017.2391","article-title":"Measuring toxic Effects and Time to Treatment failure for Nivolumab Plus Ipilimumab in Melanoma","volume":"4","author":"Shoushtari","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bcp.2026.118530_b0030","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118530_b0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev-cancerbio-030617-050549","article-title":"Harnessing Protease activity to Improve Cancer Care","volume":"2","author":"Dudani","year":"2018","journal-title":"Annu. Rev. Canc. Biol."},{"key":"10.1016\/j.bcp.2026.118530_b0040","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.drudis.2022.03.011","article-title":"Exploiting protease activation for therapy","volume":"27","author":"Bleuez","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bcp.2026.118530_b0045","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1158\/0008-5472.CAN-12-2796","article-title":"Acidity Generated by the Tumor Microenvironment Drives Local Invasion","volume":"73","author":"Estrella","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118530_b0050","first-page":"4373","article-title":"Acid pH in tumors and its potential for therapeutic exploitation","volume":"49","author":"Tannock","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118530_b0055","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/BF01504608","article-title":"\u00dcber den Stoffwechsel der Carcinomzelle","volume":"12","author":"Warburg","year":"1924","journal-title":"Naturwissenschaften"},{"key":"10.1016\/j.bcp.2026.118530_b0060","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1373\/clinchem.2006.076364","article-title":"Human Plasma ATP Concentration","volume":"53","author":"Buffington","year":"2007","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bcp.2026.118530_b0065","doi-asserted-by":"crossref","unstructured":"El Khoury, J. et al. (2008) Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase. PLoS ONE 3. 10.1371\/journal.pone.0002599.","DOI":"10.1371\/journal.pone.0002599"},{"key":"10.1016\/j.bcp.2026.118530_b0070","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41419-022-04647-6","article-title":"Extracellular ATP promotes breast cancer chemoresistance via HIF-1\u03b1 signaling","volume":"13","author":"Yang","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2026.118530_b0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1126\/scitranslmed.3006682","article-title":"Tumor-specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index","volume":"5","author":"Desnoyers","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2026.118530_b0080","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01399-4","article-title":"A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety","volume":"16","author":"Li","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.118530_b0085","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-47256-x","article-title":"VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response","volume":"15","author":"Thisted","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118530_b0090","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2159-8290.CD-20-0328","article-title":"Antibody to CD137 Activated by Extracellular Adenosine Triphosphate is Tumor Selective and Broadly EffectiveIn Vivowithout Systemic Immune Activation","volume":"11","author":"Kamata-Sakurai","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118530_b0095","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1158\/1535-7163.MCT-24-0371","article-title":"Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47","volume":"24","author":"Levengood","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2026.118530_b0100","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1182\/blood-2021-152130","article-title":"ADG153, an Anti-CD47 Monoclonal Antibody Prodrug, has strong In Vivo Anti-Tumor activity, Minimal RBC-Related and Antigen Sink Liabilities, and Extended half Life in Comparison with Benchmark Clinical Antibodies of the same IgG Subclass","volume":"138","author":"Cai","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118530_b0105","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41587-019-0135-x","article-title":"A coiled-coil masking domain for selective activation of therapeutic antibodies","volume":"37","author":"Trang","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcp.2026.118530_b0110","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1158\/0008-5472.CAN-21-2483","article-title":"A Probody T Cell\u2013Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity","volume":"82","author":"Boustany","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118530_b0115","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1515\/hsz-2018-0451","article-title":"The multifaceted roles of tumor-associated proteases and harnessing their activity for prodrug activation","volume":"400","author":"Vasiljeva","year":"2019","journal-title":"Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118530_b0120","first-page":"7367","article-title":"Acidic extracellular microenvironment promotes the invasion and cathepsin B secretion of PC-3 cells","volume":"8","author":"Gao","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.bcp.2026.118530_b0125","doi-asserted-by":"crossref","first-page":"10940","DOI":"10.1073\/pnas.1300686110","article-title":"Mechanistic and structural studies on legumain explain its zymogenicity, distinct activation pathways, and regulation","volume":"110","author":"Dall","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118530_b0130","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/jid.2008.449","article-title":"Role of Matriptase and Proteinase-Activated Receptor-2 in Nonmelanoma Skin Cancer","volume":"129","author":"Bocheva","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bcp.2026.118530_b0135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fonc.2018.00024","article-title":"Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic applications","volume":"8","author":"Mahmood","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.118530_b0140","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/cbt.8.22.9765","article-title":"Design and development of masked therapeutic antibodies to limit off-target effects Application to anti-EGFR antibodies","volume":"8","author":"Donaldson","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bcp.2026.118530_b0145","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007785","article-title":"XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer","volume":"11","author":"Jenkins","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.118530_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.143176","article-title":"Protease-activated anti-Lewis Y antibody enhances selectivity and safety of glycan-targeting cancer therapy","volume":"309","author":"Lee","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bcp.2026.118530_b0155","doi-asserted-by":"crossref","DOI":"10.1186\/s13036-025-00517-9","article-title":"Design of a prodrug bispecific antibody masked by a functional molecule for lymphocyte activation for cancer therapy","volume":"19","author":"Miura","year":"2025","journal-title":"J. Biol. Eng."},{"key":"10.1016\/j.bcp.2026.118530_b0160","article-title":"A Conditionally Activated Cytosol-Penetrating Antibody for TME-Dependent Intracellular Cargo delivery","volume":"13","author":"Dombrowsky","year":"2024","journal-title":"Antibodies (basel)"},{"key":"10.1016\/j.bcp.2026.118530_b0165","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1110\/ps.051897806","article-title":"Bacterial display using circularly permuted outer membrane protein OmpX yields high affinity peptide ligands","volume":"15","author":"Rice","year":"2006","journal-title":"Protein Sci."},{"key":"10.1016\/j.bcp.2026.118530_b0170","doi-asserted-by":"crossref","DOI":"10.1093\/protein\/gzaf006","article-title":"A facile yeast-display approach for antibody mask discovery","volume":"38","author":"Badarinath","year":"2025","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.bcp.2026.118530_b0175","doi-asserted-by":"crossref","unstructured":"McCue, A.C. et al. (2024) Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy. mAbs 16. 10.1080\/19420862.2024.2373325.","DOI":"10.1080\/19420862.2024.2373325"},{"key":"10.1016\/j.bcp.2026.118530_b0180","doi-asserted-by":"crossref","unstructured":"Orozco, C.T. et al. (2022) Mechanistic insights into the rational design of masked antibodies. mAbs 14. 10.1080\/19420862.2022.2095701.","DOI":"10.1080\/19420862.2022.2095701"},{"key":"10.1016\/j.bcp.2026.118530_b0185","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1172\/JCI123391","article-title":"Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity","volume":"129","author":"Pai","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2026.118530_b0190","article-title":"Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118530_b0195","doi-asserted-by":"crossref","first-page":"20080","DOI":"10.1021\/jacs.4c04035","article-title":"Site-specific Antibody Prodrugs via S-Arylation: a Bioconjugation Approach Toward Masked Tyrosine Analogues","volume":"146","author":"Tao","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.118530_b0200","doi-asserted-by":"crossref","first-page":"40911","DOI":"10.1021\/acsomega.3c06216","article-title":"Development of an Albumin-Masked mutPD-1Ig as a Tumor Lesion-Selective Immune Checkpoint Inhibitor","volume":"8","author":"Chou","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bcp.2026.118530_b0205","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/2326-6066.CIR-21-0031","article-title":"Conditional PD-1\/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti\u2013PD-1\/PD-L1 Agents","volume":"9","author":"Assi","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bcp.2026.118530_b0210","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-291X(67)80055-X","article-title":"On the size of the active site in proteases. I","volume":"27","author":"Schechter","year":"1967","journal-title":"Papain. Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.bcp.2026.118530_b0215","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/bs.pmbts.2017.04.003","article-title":"Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders","volume":"148","author":"Liu","year":"2017","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.bcp.2026.118530_b0220","series-title":"Progress in Molecular Biology and Translational Science","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmbts.2017.02.005","article-title":"Chapter one - Biochemical and Biological Attributes of Matrix Metalloproteinases","author":"Cui","year":"2017"},{"key":"10.1016\/j.bcp.2026.118530_b0225","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.cardiores.2005.12.002","article-title":"Structure and function of matrix metalloproteinases and TIMPs","volume":"69","author":"Nagase","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2026.118530_b0230","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.biochi.2004.11.019","article-title":"Crystal structures of MMPs in complex with physiological and pharmacological inhibitors","volume":"87","author":"Maskos","year":"2005","journal-title":"Biochimie"},{"key":"10.1016\/j.bcp.2026.118530_b0235","article-title":"Engineering high-efficiency matriptase substrates using E. coli display for applications in prodrug activation","volume":"5","author":"Mestre Borras","year":"2025","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.bcp.2026.118530_b0240","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0969-2126(01)00203-9","article-title":"The crystal structure of the catalytic domain of human urokinase-type plasminogen activator","volume":"3","author":"Spraggon","year":"1995","journal-title":"Structure"},{"key":"10.1016\/j.bcp.2026.118530_b0245","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1074\/jbc.M109830200","article-title":"Catalytic Domain Structures of MT-SP1\/Matriptase, a Matrix-degrading Transmembrane Serine Proteinase*","volume":"277","author":"Friedrich","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118530_b0680","doi-asserted-by":"crossref","first-page":"e4578","DOI":"10.1002\/pro.4578","article-title":"Design of a protease-activated PD-L1 inhibitor","volume":"32","author":"Goudy","year":"2023","journal-title":"Protein Sci."},{"key":"10.1016\/j.bcp.2026.118530_b0400","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jconrel.2023.01.041","article-title":"Microenvironment-responsive anti-PD-L1\u00d7CD3 bispecific T-cell engager for solid tumor immunotherapy","volume":"354","author":"Liu","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2026.118530_b0685","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.cdd.4401735","article-title":"Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug","volume":"13","author":"Gerspach","year":"2006","journal-title":"Cell Death & Differentiation"},{"key":"10.1016\/j.bcp.2026.118530_b0690","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.715719","article-title":"Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity","volume":"12","author":"Elter","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118530_b0695","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.1038\/s41598-020-62339-7","article-title":"Monitoring protease activity in biological tissues using antibody prodrugs as sensing probes","volume":"10","author":"Vasiljeva","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118530_b0660","article-title":"Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy","volume":"17","author":"Cadwell","year":"2019","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bcp.2026.118530_b0700","article-title":"Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies","author":"Huang","year":"2021","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bcp.2026.118530_b0705","doi-asserted-by":"crossref","DOI":"10.1186\/s41232-023-00264-8","article-title":"A lesion-selective albumin-CTLA4Ig as a safe and effective treatment for collagen-induced arthritis","volume":"43","author":"Jiang","year":"2023","journal-title":"Inflammation and Regeneration"},{"key":"10.1016\/j.bcp.2026.118530_b0250","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16838-w","article-title":"Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody","volume":"11","author":"Geiger","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118530_b0670","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jconrel.2012.05.035","article-title":"Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases","volume":"161","author":"Erster","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2026.118530_b0310","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/19420862.2015.1008352","article-title":"Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency","volume":"7","author":"Yang","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.bcp.2026.118530_b0255","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jitc-2021-002446","article-title":"CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study","volume":"9","author":"Sanborn","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.118530_b0260","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/jitc-2021-002447","article-title":"CX-072 (pacmilimab), a Probody\u00ae PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study","volume":"9","author":"Naing","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.118530_b0265","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1200\/JCO.2025.43.16_suppl.3553","article-title":"Vilastobart (XTX101), a tumor-activated, Fc-enhanced anti\u2013CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with MSS CRC","volume":"43","author":"Fakih","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118530_b0270","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1073\/pnas.2025930118","article-title":"Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic","volume":"118","author":"Etxeberria","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118530_b0275","unstructured":"Du, F. et al. (2023). Anti-CD3 Antibodies and Methods of Use Thereof. CN117255801A, 2023. Available at: https:\/\/patentimages.storage.googleapis.com\/19\/b1\/db\/e109b661bfeb16\/CN117255801A.pdf (accessed: 11 May 2026)."},{"key":"10.1016\/j.bcp.2026.118530_b0280","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1158\/1538-7445.AM2021-1853","article-title":"Abstract 1853: a novel anti-CTLA-4 checkpoint inhibitor prodrug to address on-target off-tumor toxicity for cancer immunotherapy","volume":"81","author":"Liu","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118530_b0285","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1158\/1538-7445.AM2023-2930","article-title":"Abstract 2930: ADG153, a novel masked anti-CD47 IgG1 SAFEbody, demonstrates strong in vivo anti-tumor activities in preclinical solid tumor models and preferential CD47 target engagement in the tumor microenvironment","volume":"83","author":"Nguyen","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118530_b0290","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1158\/1538-7445.AM2022-4257","article-title":"Abstract 4257: ADG153-G1, a highly differentiated anti-CD47 IgG1 SAFEbody, demonstrates potent in vivo anti-tumor activities with enhanced ADCC\/ADCP effects and significantly reduced RBC-related and antigen sink liabilities","volume":"82","author":"Cai","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118530_b0295","doi-asserted-by":"crossref","first-page":"S882","DOI":"10.1016\/j.annonc.2022.07.867","article-title":"741P phase I results demonstrate highly differentiated safety and PK profile of ADG126, a masked anti-CTLA-4 SAFEbody in patients with advanced solid tumors","volume":"33","author":"Richardson","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.118530_b0300","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1200\/JCO.2025.43.16_suppl.3579","article-title":"Safety and efficacy of ADG126 (an anti-CTLA-4 masking antibody) in combination with pembrolizumab: Updated results of phase 1b\/2 study in advanced MSS CRC","volume":"43","author":"Li","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118530_b0305","article-title":"Abstract CT054: results from the phase 1b\/2 Morpheus liver study in patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC): Muzastotug (ADG126: masked anti-CTLA-4 Ab) combination arm","volume":"86","author":"Li","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118530_b0315","doi-asserted-by":"crossref","DOI":"10.1593\/neo.121242","article-title":"Functional Dissection of the Epidermal Growth factor Receptor Epitopes Targeted by Panitumumab and Cetuximab","volume":"14","author":"Voigt;","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.bcp.2026.118530_b0320","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody\u2013drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118530_b0325","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118530_b0330","article-title":"CAR-T cells in solid tumors: challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bcp.2026.118530_b0335","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bcp.2026.118530_b0340","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2026.118530_b0345","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s43018-023-00536-9","article-title":"Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors","volume":"4","author":"Cattaruzza","year":"2023","journal-title":"Nature Cancer"},{"key":"10.1016\/j.bcp.2026.118530_b0350","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/19420862.2015.1127491","article-title":"Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy","volume":"8","author":"Yang","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.bcp.2026.118530_b0355","unstructured":"(2026). Available at: https:\/\/cytomx.com\/wp-content\/uploads\/WADC2026final.pdf (accessed: 10 May 2026)."},{"key":"10.1016\/j.bcp.2026.118530_b0360","unstructured":"(2023). Available at: https:\/\/cytomx.com\/wp-content\/uploads\/CytomX-WADC-CX-2051-Oct-2023-vF.pdf (accessed: 10 May 2026)."},{"key":"10.1016\/j.bcp.2026.118530_b0365","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118530_b0370","doi-asserted-by":"crossref","unstructured":"Ball, K. et al. (2023) Strategies for clinical dose optimization of T cell-engaging therapies in oncology. mAbs 15. 10.1080\/19420862.2023.2181016.","DOI":"10.1080\/19420862.2023.2181016"},{"key":"10.1016\/j.bcp.2026.118530_b0375","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1523693","article-title":"Prodrug-based bispecific antibodies for cancer therapy: advances and future directions","volume":"16","author":"Ai","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118530_b0380","unstructured":"(2022). Available at: https:\/\/www.januxrx.com\/wp-content\/uploads\/2022\/11\/DiRaimondo_EGFR-poster_Final_SITC2022.pdf (accessed: 10 May 2026)."},{"key":"10.1016\/j.bcp.2026.118530_b0385","unstructured":"(2022). Available at: https:\/\/www.januxrx.com\/wp-content\/uploads\/2022\/11\/DiRaimondo_PSMA-poster_Final_SITC2022.pdf (accessed: 10 May 2026)."},{"key":"10.1016\/j.bcp.2026.118530_b0435","doi-asserted-by":"crossref","unstructured":"Panchal, A. et al. (2020) COBRA\u2122: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors. mAbs 12. 10.1080\/19420862.2020.1792130.","DOI":"10.1080\/19420862.2020.1792130"},{"key":"10.1016\/j.bcp.2026.118530_b0390","unstructured":"(2026). Available at: https:\/\/investors.januxrx.com\/investor-media\/news\/news-details\/2026\/Janux-Therapeutics-Announces-Discontinuation-of-JANX008-Clinical-Development\/default.aspx (accessed: 10 May 2026)."},{"key":"10.1016\/j.bcp.2026.118530_b0395","unstructured":"(2025). Available at: https:\/\/investors.januxrx.com\/investor-media\/news\/news-details\/2025\/Janux-Announces-Encouraging-Efficacy-and-Safety-Profile-from-Ongoing-Phase-1-Clinical-Trial-for-JANX007-in-mCRPC\/default.aspx (accessed: 10 May 2026)."},{"key":"10.1016\/j.bcp.2026.118530_b0405","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nbt.1588","article-title":"A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner","volume":"27","author":"Schellenberger","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcp.2026.118530_b0410","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jconrel.2015.10.038","article-title":"Extension of in vivo half-life of biologically active molecules by XTEN protein polymers","volume":"240","author":"Podust","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2026.118530_b0415","doi-asserted-by":"crossref","unstructured":"(2026). Available at: https:\/\/s203.q4cdn.com\/628578897\/files\/doc_financials\/2026\/q1\/Vir-Bio-Corporate-Overview-May-2026.pdf (accessed: 10 May 2026).","DOI":"10.22233\/20412495.0526.1"},{"key":"10.1016\/j.bcp.2026.118530_b0420","unstructured":"(2026). Available at: https:\/\/investors.januxrx.com\/investor-media\/news\/news-details\/2026\/Janux-Therapeutics-Announces-First-Participant-Dosed-in-Phase-1-Study-of-JANX014\/default.aspx (accessed: 10 May 2026)."},{"key":"10.1016\/j.bcp.2026.118530_b0425","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/bph.13499","article-title":"Genetic fusion of human FGF21 to a synthetic polypeptide improves pharmacokinetics and pharmacodynamics in a mouse model of obesity","volume":"173","author":"Yin","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118530_b0430","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1038\/s41467-018-07136-7","article-title":"Structure of the 4-1BB\/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab","volume":"9","author":"Chin","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118530_b0440","doi-asserted-by":"crossref","unstructured":"Sun, R. et al. (2025) Heterogeneous and evolving epitope landscape of clinical anti-drug antibodies against multidomain biotherapeutic: a case study of TAK-186. mAbs 17. 10.1080\/19420862.2025.2587584.","DOI":"10.1080\/19420862.2025.2587584"},{"key":"10.1016\/j.bcp.2026.118530_b0445","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2026.118530_b0450","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics18040468","article-title":"Antibody\u2013Drug Conjugates: Pharmacotherapeutic Properties and Future Perspectives","volume":"18","author":"Augusto","year":"2026","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bcp.2026.118530_b0455","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/1535-7163.MCT-21-0193","article-title":"Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody\u2013Drug Conjugate","volume":"21","author":"Singh","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2026.118530_b0460","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1158\/1078-0432.CCR-21-0194","article-title":"Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in adults with Advanced Solid Tumor Malignancies","volume":"27","author":"Johnson","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118530_b0465","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.7150\/thno.44334","article-title":"The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice","volume":"10","author":"Chomet","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2026.118530_b0480","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1258700","article-title":"Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting","volume":"14","author":"Schoenfeld","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118530_b0470","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-21-3656","article-title":"Praluzatamab Ravtansine, a CD166-Targeting Antibody\u2013Drug Conjugate, in patients with Advanced Solid Tumors: an Open-Label phase I\/II Trial","volume":"28","author":"Boni","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118530_b0475","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-P4-01-15","article-title":"Abstract P4-01-15: Preliminary results from a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC)","volume":"83","author":"Miller","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118530_b0485","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T Cell Therapy: the Efficacy and Toxicity Balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.bcp.2026.118530_b0490","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17172898","article-title":"Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions","volume":"17","author":"Rafii","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2026.118530_b0495","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","article-title":"High-Affinity GD2-specific CAR T Cells Induce Fatal Encephalitis in a Preclinical neuroblastoma Model","volume":"6","author":"Richman","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bcp.2026.118530_b0500","doi-asserted-by":"crossref","unstructured":"Wang, L. et al. (2023) A novel microenvironment regulated system CAR-T (MRS.CAR-T) for immunotherapeutic treatment of esophageal squamous carcinoma. Cancer Letters 568. 10.1016\/j.canlet.2023.216303.","DOI":"10.1016\/j.canlet.2023.216303"},{"key":"10.1016\/j.bcp.2026.118530_b0505","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ymthe.2016.10.011","article-title":"Masked Chimeric Antigen Receptor for Tumor-specific Activation","volume":"25","author":"Han","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2026.118530_b0510","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1158\/0008-5472.CAN-21-2931","article-title":"Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma","volume":"82","author":"Panowski","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118530_b0515","article-title":"CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models","volume":"6","author":"Shang","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bcp.2026.118530_b0520","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26199367","article-title":"Distance-Dependent distribution of Biomarkers in Colorectal Cancer Tissues: In Vivo Study","volume":"26","author":"Sebzda","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118530_b0525","doi-asserted-by":"crossref","unstructured":"\u0106wilichowska-Pu\u015blecka, N. et al. (2026) Single-cell and spatial profiling of cysteine cathepsins identifies tumor states relevant to antibody-drug conjugates in breast cancer. medRxiv, 2026.2005.2010.26352827. 10.64898\/2026.05.10.26352827.","DOI":"10.64898\/2026.05.10.26352827"},{"key":"10.1016\/j.bcp.2026.118530_b0530","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-64081-y","article-title":"A next-generation anti-CTLA-4 probody mitigates toxicity and enhances anti-tumor immunity in mice","volume":"16","author":"Cao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118530_b0535","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s42255-020-0172-2","article-title":"We need to talk about the Warburg effect","volume":"2","author":"DeBerardinis","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.bcp.2026.118530_b0540","doi-asserted-by":"crossref","first-page":"C89","DOI":"10.1152\/ajpcell.00285.2013","article-title":"Physical biology in cancer. 3. the role of cell glycocalyx in vascular transport of circulating tumor cells","volume":"306","author":"Mitchell","year":"2014","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.bcp.2026.118530_b0545","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00424-009-0694-7","article-title":"The glycocalyx maintains a cell surface pH nanoenvironment crucial for integrin-mediated migration of human melanoma cells","volume":"458","author":"Kr\u00e4hling","year":"2009","journal-title":"Pfl\u00fcgers Archiv - European Journal of Physiology"},{"key":"10.1016\/j.bcp.2026.118530_b0550","series-title":"Proceedings of the National Academy of Sciences 118","article-title":"Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches","author":"Chang","year":"2021"},{"key":"10.1016\/j.bcp.2026.118530_b0555","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.omto.2022.11.001","article-title":"A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering","volume":"27","author":"Liu","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.bcp.2026.118530_b0560","doi-asserted-by":"crossref","first-page":"22284","DOI":"10.1021\/jacs.4c04647","article-title":"Proton transfer Kinetics in Histidine Side Chains Determined by pH-dependent Multi-Nuclear NMR Relaxation","volume":"146","author":"Raum","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.118530_b0565","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.str.2024.02.009","article-title":"Structural insights into the unique pH-responsive characteristics of the anti-TIGIT therapeutic antibody Ociperlimab","volume":"32","author":"Sun","year":"2024","journal-title":"Structure"},{"key":"10.1016\/j.bcp.2026.118530_b0570","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","article-title":"VISTA is an acidic pH-selective ligand for PSGL-1","volume":"574","author":"Johnston","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118530_b0575","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1200\/JCO.2024.42.16_suppl.2600","article-title":"Initial results from a first-in-human phase 1 study of SNS-101 (pH-selective anti-VISTA antibody) alone or in combination with cemiplimab in patients with advanced solid tumors","volume":"42","author":"Sen","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118530_b0580","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41551-022-00956-5","article-title":"An anti-CD98 antibody displaying pH-dependent Fc-mediated tumour-specific activity against multiple cancers in CD98-humanized mice","volume":"7","author":"Tian","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bcp.2026.118530_b0590","doi-asserted-by":"crossref","unstructured":"Sulea, T. et al. (2019) Structure-based engineering of pH-dependent antibody binding for selective targeting of solid-tumor microenvironment. mAbs 12. 10.1080\/19420862.2019.1682866.","DOI":"10.1080\/19420862.2019.1682866"},{"key":"10.1016\/j.bcp.2026.118530_b0650","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013397","article-title":"ROSE12, a novel anti-CTLA-4 Fc\u03b3Rs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation","volume":"14","author":"Hayashi","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.118530_b0585","doi-asserted-by":"crossref","unstructured":"Lee, P.S. et al. (2022) Improved therapeutic index of an acidic pH-selective antibody. mAbs 14. 10.1080\/19420862.2021.2024642.","DOI":"10.1080\/19420862.2021.2024642"},{"key":"10.1016\/j.bcp.2026.118530_b0595","article-title":"Assisted Design of Antibody and Protein Therapeutics (ADAPT)","volume":"12","author":"Fraternali","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2026.118530_b0600","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/prot.26340","article-title":"Antibody mutations favoring pH\u2010dependent binding in solid tumor microenvironments: Insights from large\u2010scale structure\u2010based calculations. Proteins: Structure","volume":"90","author":"Wei","year":"2022","journal-title":"Function, and Bioinformatics"},{"key":"10.1016\/j.bcp.2026.118530_b0605","series-title":"3 Biotech 12","article-title":"A stepwise mutagenesis approach using histidine and acidic amino acid to engineer highly pH-dependent protein switches","author":"Zou","year":"2021"},{"key":"10.1016\/j.bcp.2026.118530_b0610","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1200\/JCO.2024.42.16_suppl.2602","article-title":"Phase 1 study of BA3071, an anti\u2013CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors","volume":"42","author":"Thomas","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118530_b0615","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1038\/s41467-020-17756-7","article-title":"T-cells produce acidic niches in lymph nodes to suppress their own effector functions","volume":"11","author":"Wu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118530_b0620","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41590-022-01176-4","article-title":"LAG3 associates with TCR\u2013CD3 complexes and suppresses signaling by driving co-receptor\u2013Lck dissociation","volume":"23","author":"Guy","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bcp.2026.118530_b0625","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nm0297-177","article-title":"Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation","volume":"3","author":"Helmlinger","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.118530_b0630","doi-asserted-by":"crossref","DOI":"10.3390\/cancers18081193","article-title":"Tumor Microenvironment Acidosis and Alkalization-Oriented Interventions in Advanced Solid Tumors: a Narrative Review and Science-based Medicine Perspective on Long-Tail Survival","volume":"18","author":"Suzuki","year":"2026","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2026.118530_b0635","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/onc.2016.206","article-title":"Extracellular purines, purinergic receptors and tumor growth","volume":"36","author":"Di Virgilio","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.118530_b0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108542","article-title":"Exploitation of Elevated Extracellular ATP to specifically Direct Antibody to Tumor Microenvironment","volume":"33","author":"Mimoto","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2026.118530_b0645","doi-asserted-by":"crossref","first-page":"6457","DOI":"10.1158\/1538-7445.AM2026-6457","article-title":"Abstract 6457: phase I study of STA551 (STA) a tumor-selective CD137 agonist, as monotherapy and in combination with atezolizumab (atezo) using CD8 PET imaging to assess pharmacodynamic effects","volume":"86","author":"Banerji","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118530_b0655","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197151","article-title":"CD39 is upregulated during activation of mouse and human T cells and attenuates the immune response to Listeria monocytogenes","volume":"13","author":"Raczkowski","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2026.118530_b0665","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1002\/art.39232","article-title":"Rational Design of Antirheumatic Prodrugs Specific for Sites of Inflammation","volume":"67","author":"Onuoha","year":"2015","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.bcp.2026.118530_b0675","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1021\/acschembio.5c00774","article-title":"Evaluating BindCraft for Generative Design of High-Affinity Peptides","volume":"20","author":"Filius","year":"2025","journal-title":"ACS Chem. Biol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:45:43Z","timestamp":1791963943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226008725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":141,"alternative-id":["S0006295226008725"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118530","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in tumor microenvironment-responsive pro-antibody to overcome on-target, off-tumor toxicity","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118530","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118530"}}